Accord has launched Delmosart (methylphenidate) Prolonged-release 18mg, 27mg, 36mg and 54mg Tablets as part its portfolio of branded generics. Delmosart, a Schedule 2 controlled drug, is indicated as part of a treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged six years of age and over when remedial measures alone prove insufficient.

Jonathan Wilson, managing director of Accord UK comments: “Our portfolio of branded generics is an important part of the Accord business and we are committed to offering a market competitive price to both pharmacists and the NHS. Having listened to our customers’ needs, we are now offering further potential cost savings to the NHS with the addition of Delmosart to our extensive range of products.”

ACCORD freephone 0800 731 0370 or fax 0800 731 0380